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Summary
Background.— Fetal tachycardias result in serious prenatal and postnatal morbidity and mortal-
ity. Intrauterine treatment can improve prognosis dramatically and the therapeutic protocol is
well deﬁned. Currently, amiodarone is used as third-line therapy and is reserved for refractory
cases.
Aims.— Our aim was to review the management and outcome of fetal tachycardia, giving
particular consideration to the efﬁcacy and safety of amiodarone therapy.
Methods.— This was a retrospective study of 24 consecutive cases of sustained fetal tachy-
cardia, treated mainly with digoxin and/or amiodarone administered by the transplacental
route.
Results.— The 24 fetal tachycardias comprised 16 supraventricular tachycardias with 1:1 atri-
oventricular conduction, seven atrial ﬂutters and one ventricular tachycardia. Seven fetuses
were hydropic and eight experienced less severe cardiac failure. Digoxin monotherapy con-
verted 5/12 non-hydropic fetuses and 0/2 hydropic fetuses, with one intrauterine death.
Amiodarone monotherapy converted 5/5 fetuses, including two hydropic fetuses: one ventric-
ular tachycardia, two atrial ﬂutters and two supraventricular tachycardias. When administered
with digoxin, amiodarone converted all but two fetuses (7/9). No deaths were associated
om (P.G. Pézard).
2008 Elsevier Masson SAS. All rights reserved.
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therapy.
Conclusion.— Maternal oral amiodarone seems to be effective and relatively safe, even in
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Conclusion.— L’administration d’amiodarone par voie orale à la mère semble efﬁcace et
relativement bien tolérée, même en cas d’anasarque. Cette série suggère qu’il est envisageable
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bbreviations
AET atrial ectopic tachycardia
GW gestational weeks
SVT supraventricular tachycardia
TSH thyroid stimulating hormone
VT ventricular tachycardia
ackground
he management of fetal tachycardia is one of the most
timulating ﬁelds in prenatal cardiology. Fetal tachycardias
esult in serious prenatal and postnatal morbidity and mor-
ality [1,2], particularly if a non-immune fetal hydrops is
resent [3,4]. Intrauterine treatment can, however, improve
rognosis dramatically. Over the past 25 years, almost all
ntiarrhythmic agents have been tested via different admin-
stration routes, either transplacental or directly to the
etus by intracordonal, intramuscular or intraperitoneal
njections [5—10]. This extensive experience has enabled
he selection of four main drugs (digoxin, Flecainide®,
otalol, and amiodarone) and the deﬁnition of their means
f administration [11—13]; it has also identiﬁed the risks
nd complications associated with the use of antiarrhythmic
rugs during fetal life [14,15].
The literature published on this topic usually reports on
he use of two or three lines of treatment, with amiodarone
eing used as a last resort and reserved for refractory cases
6,8—10,15,16]. Our retrospective study of 24 cases of fetal
achycardia documents the earlier and more extensive use
f amiodarone both as monotherapy and as ﬁrst-line treat-
ent.
•ac¸on plus précoce qu’il n’est admis habituellement.
rights reserved.
ethods
e reviewed all cases of sustained fetal tachycardia (exclud-
ng sinus tachycardia) managed by the prenatal unit of
ngers University Hospital between 1986 and 2007, which
omprised 23 cases of SVT and one case of VT.
iagnosis
iagnosis of the arrhythmia was established by M-mode fetal
chocardiography using the following criteria:
fast and identical atrial rate and ventricular rate
(> 200 bpm) (SVT with atrioventricular conduction ratio of
1:1 conforming to a re-entry SVT or an AET);
fast atrial rate (> 300 bpm) associated with a lower ven-
tricular rate demonstrating 2:1 or greater atrioventricular
block conforming to an atrial ﬂutter;
complete dissociation between fast ventricular rate
(> 200 bpm) and lower atrial rate, conforming to VT.
etal tolerance
etal tolerance was subdivided into three groups according
o the severity of two-dimensional and Doppler echographic
ndings of fetal haemodynamic compromise:
poor tolerance with hydrops, with at least two of the fol-
lowing signs present—ascites, pleural effusion, abundant
pericardial effusion, moderate to severe tricuspid valveP.G. Pézard et al.
with amiodarone, but there was moderate morbidity, with six transient elevations of thyroid
stimulating hormone at birth, two of which required short-term thyroid hormonal substitutionhydropic fetuses. We suggest that this treatment could be used earlier than is currently advised.
© 2008 Elsevier Masson SAS. All rights reserved.
Résumé
Objectifs.— Évaluer l’efﬁcacité et la sécurité d’emploi de l’amiodarone administrée par voie
transplacentaire pour traiter une tachycardie fœtale in utero.
Méthodes.— Étude rétrospective de 24 tachycardies fœtales soutenues consécutives traitées
principalement par digoxine et/ou amiodarone par voie transplacentaire.
Résultats.— Il a été observé 16 tachycardies supraventriculaires (TSV) avec conduction 1/1,
sept ﬂutter auriculaires et une tachycardie ventriculaire (TV). Sept fœtus étaient en anasarque
et huit présentaient des signes de mauvaise tolérance moins sévères. La digoxine seule a régu-
larisé 5/12 fœtus sans anasarque et 0/2 avec anasarque, avec un décès in utero. L’amiodarone
en monothérapie a régularisé 5/5 tachycardies : une TV, deux ﬂutter et deux TSV 1/1, dont
deux chez des fœtus en anasarque. L’association digoxine—amiodarone a été efﬁcace dans 7/9
cas. Il n’y a pas eu de décès sous amiodarone, mais il a été observé six élévations transitoires
de la TSH à la naissance, dont deux ont justiﬁé un traitement substitutif durant les premières
semaines de vie.regurgitation, skin oedema and polyhydramnios;
intermediate tolerance, when a small pericardial or
abdominal effusion, a hydrocoele and/or a mild tricuspid
valve regurgitation were present and disappeared after
conversion to sinus rhythm;
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• good tolerance, when none of the above symptoms was
present.
Treatment
Transplacental treatment was always initiated in the hospi-
tal setting. Digoxin and amiodarone were administered to
the mother by the oral route in the following ways:
• amiodarone, loading dose 1600—2400mg/day two to four
times daily usually halved every 24 hours, maintenance
dose 200—400mg/day twice daily;
• digoxin, loading dose 1—1.5mg/day twice daily, mainte-
nance dose 0.5mg/day.
To enable assessment of the neonate without treatment,
amiodarone was withdrawn 15—21 days before term and
digoxin was discontinued a few days before delivery.
Statistical analysis
When appropriate, statistical analysis was performed using
the non-paired Student’s t test. Differences were considered
to be signiﬁcant at a p-value of less or equal to 0.05.
Results
About 70,000 births occurred in our centre during the study
period; we identiﬁed 24 cases of fetal tachycardia, which
gives an approximate incidence of 0.3 cases per 1000 births.
Clinical characteristics
The principal data on the 24 tachycardias are summarized
in Tables 1—3, according to the intensity of fetal haemody-
namic failure.
The tachycardia mechanism was supraventricular in 23
cases and originated from the ventricle in one case (con-
ﬁrmed postnatally). It became apparent that out of the 14
SVT with a 1:1 atrioventricular conduction ratio, 11 were
re-entry tachycardias and four were AET. Seven cases corre-
sponded to atrial ﬂutter (35%). In one case, the mechanism
of the SVT could not be ascertained in utero (one short run
with spontaneous resolution) and was conﬁrmed only after
the recurrence of re-entry SVT after birth.
The ventricular rate was slower in cases of atrial ﬂut-
ter (200± 37 bpm, range 160—270 bpm) than in re-entry SVT
(263± 44 bpm, range 210—360 bpm; p < 0.05). The ventricu-
lar rates of the four AET ranged from 225 to 280 bpm.
The gestational age at presentation ranged from 21 to
37 GW (mean 30.1± 4.6GW) with 12 arrhythmias occurring
before 32GW and 12 at or after 32GW. All cases of atrial
ﬂutter were discovered after 30GW.
At initial evaluation, seven fetuses were hydropic (29%;
four SVT, one AET and two atrial ﬂutters) and eight fetuses
had signs of intermediate tolerance (33%; ﬁve re-entry SVT,
one AET and two atrial ﬂutters), with the remaining nine
fetuses showing no apparent haemodynamic disturbance
(35%; three re-entry SVT, two AET, three atrial ﬂutters and
one VT). None of the 24 fetuses had any associated cardiac
or extracardiac morphological abnormalities.
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reatment
sustained sinus rhythm was obtained medically in 18 cases,
nd spontaneously (i.e. before any treatment was admin-
stered) in one case. First-line therapy was successful in
0 cases. Six cases required second-line therapy, and two
ases required third-line therapy.
In four fetuses (two AET and two re-entry SVT), treat-
ent failed to restore sinus rhythm but resulted in a slower
entricular rate with haemodynamic improvement, allowing
he pregnancy to continue for a further 4—15 weeks.
One intrauterine death was observed after eight days
f treatment with digoxin that had failed to produce any
oticeable effect on a 34GW fetus with no cardiac malfor-
ation (conﬁrmed by autopsy) and who presented initially
ith atrial ﬂutter (ventricular rate 160 bpm) and severe
ydrops.
The mean time interval from diagnosis to conversion to
inus rhythm was 5.8± 4.7 days (range 1—17 days; n = 15).
he mean time interval between the start of the efﬁcient
reatment and conversion to sinus rhythm was 4.9± 3.6 days
range 1—15 days; n = 18).
The antiarrhythmic agents used were mainly digoxin
16 cases) and amiodarone (14 cases). The peak digoxin
erum level was 1.69± 1.09 ng/ml (n = 15), with a sig-
iﬁcantly higher level when digoxin was associated with
miodarone (2.36± 1.27 ng/ml) than when used alone
1.08± 0.44 ng/ml; p < 0.05). Verapamil, Flecainide®, ciben-
oline and sotalol were used infrequently (ﬁve cases only);
f these, only sotalol was shown to be effective (Case 21; re-
ntry SVT). Cibenzoline reduced STV runs without sustained
onversion to sinus rhythm (Case 10; AET).
To summarize, the conversion to sinus rhythm could be
ttributed to:
digoxin alone in ﬁve cases (two re-entry SVT and three
atrial ﬂutters);
amiodarone alone in ﬁve cases (two re-entry SVT, two
atrial ﬂutters and one VT);
amiodarone—digoxin dual therapy in seven cases (ﬁve re-
entry SVT, one AET and one atrial ﬂutter);
digoxin—sotalol dual therapy in one case (one re-entry
SVT).
Digoxin monotherapy was never effective when hydrops
as present; it enabled conversion to sinus rhythm in
nly 2/7 fetuses, all of whom had intermediate haemody-
amic tolerance. Amiodarone monotherapy was effective
n all cases in which it was used (two cases with hydrops
nd one case with intermediate tolerance). In one AET
ase (Case 23), in whom digoxin—amiodarone dual ther-
py had failed, the association of digoxin 0.5mg/day with
lecainide® 300mg/day also failed, despite serum levels of
hese drugs being in the therapeutic range in maternal sam-
les (digoxin 1.9 ng/ml; Flecainide® 0.7mg/l) and cordonal
amples (digoxin 0.7 ng/ml; Flecainide® 0.6mg/l). Conver-
ion was obtained with amiodarone after birth.irth and postnatal progression
he mode of delivery was caesarean section in seven
ases, only two of which were partially (Case 5) or
otally (Case 23) related to the arrhythmia. Other than
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Table 1 Presentation of SVT with good haemodynamic tolerance.
Initial presentation Age (GW) Heart rate
(bpm)
Treatment Result (delay in days) Birth mode Age (GW) Weight (g) Follow-up ECG Recurrence
Re-entry SVT
Case 4 34 210 Digoxin Failure
Digoxin—amiodarone Control (7) Delivery 40 3150 Normal No
Case 12 22 270 Digoxin Control (10) Caesarean 37 3400 Normal No
Case 16 37 250 — Spontaneous Caesarean 38 2970 WPW (Kent) Yes
AET
Case 9 21 230 Digoxin Partial control Delivery 36 2820 SVT (160 bpm) Yes
Case 10 29 225 Flecainide® Maternal intolerance
Cibenzoline Partial control Delivery 39 3510 AET Yes
Atrial ﬂutter
Case 7 30 200 Amiodarone Control (3) Delivery — — Normal No
Case 15 31 170 Digoxin Control (2) Delivery 39 3680 Normal No
Case 21 32 184 Digoxin Control (5) Delivery 41 3980 Normal No
VT
Case 19 34 240 Amiodarone Control (1) Delivery 40 2865 VT runs Recovery
1month
Cases are numbered in chronological order. AET: atrial ectopic tachycardia; bpm: beats per minute; caesarean: programmed caesarean section; delivery: vaginal delivery; ECG:
electrocardiogram; GW: gestational weeks; SVT: supraventricular tachycardia; WPW: Wolff-Parkinson-White syndrome; VT: ventricular tachycardia.
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Table 2 Presentation of SVT with intermediate haemodynamic tolerance.
Initial presentation Age (GW) Heart rate
(bpm)
Treatment Result (delay
in days)
Birth mode Age (GW) Weight (g) Follow-up ECG Recurrence Thyroid
Re-entry SVT
Case 11 30 250 Digoxin Failure (1) TSH+ goiter
Digoxin—
amiodarone
Control (4) Caesarean 37 3450 Normal No l-thyroxin
2months
Case 14 22 250 Digoxin Failure (4)
Digoxin—
amiodarone
Control (5) Caesarean 41 3600 Normal No
Case 22 27 220 Digoxin Failure (13)
Digoxin—
sotalol
Control (4) Delivery 39 3460 Normal No
Case 17 33 270 Digoxin Control (1) Delivery 40 3190 Normal No
Case 24 36 270 Amiodarone Control (3) Delivery 39 3275 WPW (Kent) Yes
AET
Case 8 23 250 Digoxin Failure
Digoxin—
amiodarone
Control (15) Caesarean 38 2660 Normal No
Atrial ﬂutter
Case 20 33 220 Digoxin Failure (7) TSH+ goiter
Digoxin—
amiodarone
Control (5) Delivery 39 3690 Normal No l-thyroxin
5weeks
Case 18 34 200 Digoxin Control (3) Delivery 38 3850 Normal Yes
Cases are numbered in chronological order. AET: atrial ectopic tachycardia; bpm: beats per minute; caesarean: programmed caesarean section; delivery: vaginal delivery; ECG:
electrocardiogram; GW: gestational weeks; SVT: supraventricular tachycardia; TSH+: thyroid stimulating hormone elevation; WPW: Wolff-Parkinson-White syndrome.
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Table 3 Presentation of SVT with poor haemodynamic tolerance (hydrops).
Initial presentation Age
(GW)
Heart rate
(bpm)
Treatment Result
(delay in days)
Birth
mode
Age
(GW)
Weight
(g)
Follow-up
ECG
Recurrence Thyroid
Re-entry SVT
Case 1 25 360 Digoxin Failure
Digoxin—
verapamil
Failure
Digoxin—
amiodarone
Control (5) Delivery 40 2920 Normal No TSH+
Case 5 33 220 Flecainide® Failure (5)
Digoxin Failure (13)
Digoxin—
amiodarone
Partial control (3) Caesareana 38 3300 SVT runs Yes TSH+
Case 6 32 260 Digoxin—
amiodarone
Control (3) Delivery 36 2900 WPW
(Kent)
Yes TSH+
Case 12 31 330 Amiodarone Control (3) Delivery 38 3000 Normal No
AET
Case 23 27 280 Digoxin—
amiodarone
Failure (13)
Digoxin—
Flecainide®
Failure (7) Caesareana 31 1960 WPW
(Kent)
Yes
Atrial ﬂutter
Case 2 32 270 Amiodarone Control (10) Delivery 40 3460 Normal No TSH+
Case 3 34 160 Digoxin Failure (8) IUD 35
Cases are numbered in chronological order. AET: atrial ectopic tachycardia; bpm: beats per minute; ; delivery: vaginal delivery; ECG: electrocardiogram; GW: gestational weeks; IUD:
intrauterine death; SVT: supraventricular tachycardia; TSH+: thyroid stimulating hormone elevation; WPW: Wolff-Parkinson-White syndrome.
a Emergency caesarean section indicated by worsening of fetal status.
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these two cases, the mean gestational period at delivery
was similar for the 11 fetuses treated with amiodarone
(38.9± 1.5GW) and for the six fetuses treated with digoxin
alone (38.2± 1.9GW). We observed a slightly lower birth
weight after amiodarone treatment (3165± 329 g) than after
digoxin treatment (3400± 365 g), although this difference
was not statistically signiﬁcant.
Thyroid function was explored in all cases treated with
amiodarone. TSH levels were elevated in six neonates and
were associated with a goiter in two cases, leading us to
administer transient substitutive hormonal treatment for
ﬁve weeks and two months, respectively.
Of the 21 neonates for whom we have follow-up infor-
mation (ranging from two months to 17 years), nine infants
had recurrence of tachycardia: eight SVT required postnatal
maintenance therapy (38% of follow-up), including all four
cases that had evidence of pre-excitation on neonatal elec-
trocardiogram. The fetus with VT had some runs of VT after
birth, with spontaneous recovery at one month of life.
Discussion
The population we studied shares similarities with those
described in other reports [3,6,10,17], particularly with
regard to the frequency of fetal cardiac failure and the dis-
tribution of arrhythmias. All our cases of atrial ﬂutter were
discovered after 30GW, in line with our current knowledge
of the pathophysiology of this arrhythmia [18]. However, our
case series had an important difference in terms of the ther-
apeutic regimen adopted, and it is on this topic that we will
focus our discussion.
Fetal tachycardia requires speciﬁc management as soon
as it is sustained or if it is present for over half the time
when under observation [18]. Before 34—36GW, and espe-
cially if fetal hydrops is present, in utero management is
preferred to premature delivery, because it reduces car-
diac failure and neonatal mortality. In a study by Simpson
et al., the mortality rate of hydropic fetuses was 9.7% when
in utero conversion was successful and 56% in other cases
[3]. The choice of an antiarrhythmic agent is a compromise
between efﬁcacy and side effects, both for the mother and
the fetus. The customary dosage per kilogram used is the
same for fetuses as for adults. When the transplacental
route is adopted, the mother is inevitably exposed to high
doses of the agent. Our current understanding of the phar-
macokinetics and the sensitivity of the fetal myocardium to
antiarrhythmic drugs is embryonic. Oudjik et al. contend,
however, that the pro-arrhythmogenic effect of sotalol is
more pronounced in fetuses than in adults [12]. This risk is
illustrated by the difﬁculties reported by Simpson et al. in
their attempt to manage fetal tachycardia via cord injection
[3], and by the fetal deaths reported by others [10,14,15].
After 20 years of accumulated experience, the therapeu-
tic protocol consists of the use of four main agents and a
three-stage strategy. Digoxin is administered as ﬁrst choice,
and if it fails it is followed by Flecainide® [5,19] or sotalol [7]
either on their own or with digoxin as second-line therapy. In
this scheme, amiodarone remains on reserve for refractory
cases and is only used as a third-line agent [20].
Digoxin is used as ﬁrst choice for several reasons: it is a
well-known drug with a good evidence-based in neonates
e
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nd children. Transplacental transfer of digoxin is good,
t least in the absence of hydrops. Maternal blood levels
an be monitored easily, as long as the frequent pres-
nce of digoxin-like substances during pregnancy is taken
nto account (up to 0.5 nmol/l in our series) [21]. Digoxin
onotherapy is known to be relatively effective, regulat-
ng 60—85% of fetal tachycardias in the absence of hydrops
nd 30—50% when it is present [3]. Our own experience,
owever, is more disappointing. Digoxin alone reduced only
0% of SVT without cardiac failure and was never effective
hen fetuses were hydropic. Three elements may explain
hese mediocre results: the exclusive use of the oral route,
hen the reduced gastrointestinal absorption of digoxin
uring pregnancy usually favours intravenous administra-
ion; the fact that maternal blood levels were often below
ng/ml (although levels as low as 0.45 ng/ml have proved
ufﬁcient at times); and the replacement or combination
f digoxin with another drug in the absence of conversion
ithin 48—72 h.
Our team adopted a therapeutic strategy that differs
rom what is usually reported: we used amiodarone widely
nd early, sometimes as ﬁrst-line therapy (four SVT and one
T) and always as second-line therapy except in three cases.
his choice was based on a number of considerations. In the
arly stages of our experience, two failures occurred while
sing digoxin monotherapy for approximately 1 week (fol-
owed by a digoxin—verapamil association that also failed),
ausing the only death of this series. Consequently, we
ecided to introduce the second line of treatment earlier
n, particularly if hydrops was present. In addition, the
igoxin—amiodarone association proved to be efﬁcient and
o have a rapid onset of action, illustrated by a mean conver-
ion time of less than six days. Finally, despite the positive
esults reported with sotalol and Flecainide®, we chose not
o use these drugs because of their more marked myocardial
epressive and/or pro-arrhythmic effects compared with
miodarone, as suggested by the fatalities reported after
reatment by sotalol [18] or Flecainide® [12,21].
Our study showed amiodarone to be effective for all
etuses, whether they were hydropic or not, and whether
he agent was used alone or in association with digoxin, with
he exception of two cases: one partial effect, and one fail-
re for which Flecainide® also proved ineffective. Our series
onﬁrms observations made by Kositeth et al. [22], Jouannic
t al. [6] and Strasburger et al. [9].
Jouannic et al. used amiodarone as ﬁrst-line therapy in
he four most severe cases among 25 hydropic fetuses with
VT. They observed two conversions and one reduction in
etal heart rate without conversion. The fourth observation
as cut short by a decision to terminate the pregnancy at
4GW due to worsening hydrops. They used amiodarone as
econd-line therapy, alone or in association with digoxin in
ine cases, resulting in ﬁve conversions and three fetal heart
ate reductions compatible with the continuation of preg-
ancy. An intrauterine death occurred in the last fetus, who
as presenting severe hydrops, major ventricular hypokine-
ia, and an intraventricular haemorrhage [6].In 2004, Strasburger et al. [9] reported on the pooled
xperience of several American and Dutch teams with 26
etuses with hydrops or left ventricular dysfunction treated
y digoxin and a loading dose of amiodarone after the
ailure of one or two ﬁrst-line treatments. This treatment
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trategy converted 93% of re-entry SVT, 100% (2/2) of VT or
unctional tachycardia and 33% of atrial ﬂutter, without any
eaths at delivery. Transitory side effects were observed in
ight mothers and ﬁve neonates. This paper also reported
n the relative ineffectiveness of amiodarone in cases of
trial ﬂutter, an observation that differs from ours and
hat of Jouannic et al. [6]. More recently, Strasburger
20] contended that no fetal death linked to amiodarone
as been reported and consequently proposed the use of
miodarone with digoxin on admission in severe cases.
Fetal VT are very rare. In their case report, Schleich et al.
lso resorted to amiodarone, with partial success, although
heir case was more severe than ours, with hydrops at initial
valuation. The authors suggested that amiodarone could be
he treatment of choice for this form of tachycardia [23].
Our study suggests that amiodarone, which has been
eported to be effective after direct fetal administration
3,10,16,17], is equally so after maternal oral administra-
ion (even in hydropic cases), with a relatively rapid onset
f action despite its mediocre transplacental passage. The
etal heart may therefore be particularly sensitive to antiar-
hythmic agents, which would explain why a weak dose of
miodarone can be effective and conventional doses of other
ntiarrhythmic agents can be potentially toxic.
In our case series, maternal tolerance to amiodarone was
ood, apart from transient prolongation of the PR interval
n three mothers. No maternal thyroid complications were
bserved. Two patients given the amiodarone—digoxin com-
ination showed elevated levels of serum digoxin (up to
ng/ml) and clinical signs of digitalis intolerance, leading to
he discontinuation of the digoxin treatment and the admin-
stration of amiodarone alone. Amiodarone is known to raise
he plasma levels of digoxin, which therefore necessitates
areful dosage adjustments [24].
Fetal cardiac tolerance was also acceptable. No conduc-
ion defects or deterioration of haemodynamic status were
bserved in utero or at birth. However, as feared, thyroid
ysfunction was observed, with the appearance of a fetal
oiter leading to discontinuation of the treatment in two
etuses, and an elevation of TSH levels in six neonates,
wo of whom required short-term thyroid substituting hor-
onal treatment. Our experience is therefore similar to
ouannic et al. observation that 2/11 fetuses treated with
miodarone had an elevated TSH at birth and needed hor-
onal treatment for two and three months, respectively [6].
rematurity and small for dates are risks reported with amio-
arone use [25]. Our series did not notice the ﬁrst effect but
annot exclude the second.
To our knowledge, pulmonary and ocular complications
inked to the use of amiodarone in fetuses have not been
eported. In adults, ocular complications only appear after
wo months of treatment. Although Bartalena et al. sug-
est that amiodarone is directly neurotoxic during fetal life,
his hypothesis has not been conﬁrmed by Grosso et al.
26,27]. Nevertheless, we must attempt to keep the dura-
ion of amiodarone administration during fetal life as short
s possible. One possibility would be to use amiodarone as
rst-line therapy, either alone or combined with digoxin, and
o discontinue its use as soon as conversion occurs. Another
ntiarrhythmic agent (preferably digoxin) could be used as
aintenance therapy if indicated. This protocol was used
n our last case (Case 24), allowing for a rapid conversionP.G. Pézard et al.
o sinus rhythm with a very short exposure to amiodarone
three days) and normal thyroid hormone levels at birth.
tudy limitations
his study was retrospective and spanned 20 years, without
trict standardization of the treatment regimens. Data on
rug serum levels in mothers or neonates were missing in
ome cases. Three children born in another maternity after
onversion to sinus rhythm could not be followed up.
onclusion
his study suggests that, despite poor placental transfer,
miodarone is efﬁcient in the treatment of fetal tachycar-
ias after oral maternal administration. When amiodarone is
sed as ﬁrst-line monotherapy in hydropic fetuses, its ben-
ﬁts seem to outweigh the risks, both for the fetus and
other. The study also suggests that amiodarone may be
valuable ﬁrst-line choice for the treatment of less severe
orms of fetal STV, despite uncertainty regarding possible
he long-term effects of prolonged administration on the
etus. By resorting to this drug only during the acute phase
f treatment and withdrawing it as soon as there is conver-
ion to sinus rhythm, it may be possible to beneﬁt from
he positive therapeutic effects of amiodarone while lim-
ting exposure time to this heavily iodinized molecule and
ts potential adverse effects.
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